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Protective immunity against mycobacterial infections such as Mycobacterium tuberculosis is mediated by interactions between
specific T cells and activated antigen presenting cells. To date, many aspects of mycobacterial immunity have shown that innate
cells could be the key elements that substantially may influence the subsequent adaptive host response. During the early phases of
infection, innate lymphocyte subsets play a pivotal role in this context. Here we summarize the findings of recent investigations on
γδ T lymphocytes and their role in tuberculosis immunity.
1. Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis
(MTB), is one of the most prevalent and commonest
serious infectious diseases worldwide, aﬄicting almost 10
million people annually [1]. The disease, fuelled by Human
Immunodeficiency virus (HIV) infection and poverty, is
out of control in developing countries, and the emergence
of drug-resistant strains threatens TB control in several
other regions of the world [1, 2]. The current available
vaccine, Bacillus Calmette-Guerin (BCG) as well as existing
therapeutic interventions for TB, are at present suboptimal.
Thus, new vaccines and immunotherapeutic strategies are
urgently required to improve TB control eﬀorts [3]. A
better understanding of the immunopathogenesis of TB
could facilitate the identification of correlates of immune
protection, the design of eﬀective vaccines, the rational
selection of immunotherapeutic agents, and the evaluation
of new drug or adjuvant candidates [3, 4].
Generally, eﬀective immune responses to pathogenic
and commensal microorganisms require T lymphocytes
be endowed with eﬀector properties appropriate to each
challenge. In this context, CD4 T lymphocytes diﬀerentiate
in the peripheral tissues to adopt a variety of fates such as
the T helper (Th)-1 cells, which produce interferon (IFN)-
γ and Th-2 cells, which produce interleukin (IL)-4. Specific
cell-mediated immunity is critical in the host defense against
mycobacteria, but many aspects of mycobacterial immunity
involve other levels of responses. TB is primarily a disease
of the lung, and dissemination of the disease depends on
productive infection of this critical organ. Upon aerosol
infection with MTB, the acquired cellular immune response
is slow to be induced and to be expressed within the lung.
MTB has a variety of surface molecules and soluble products
that interact with the innate immune compartment, and this
interaction along with the autoregulation of the immune
response by several mechanisms results in less-than-optimal
control of bacterial growth. Antigen-specific γδ T cells
represent an early innate defense that may play a role in
antimycobacterial immunity. Studies done in humans and
animal models have demonstrated complex patterns of γδ T
cell immune responses during early mycobacterial infections
and chronic TB. In this paper, we focus on the role of γδ
T cells in the innate defense and the immune regulation
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of mycobacterial immunity, as well as on their possible
involvement in the new immunotherapies.
2. γδ T Cells: An Overview
The concept of a strict dependent relationship between
cells from innate and adaptive immunity changed the point
of view about the regulation of immune system. During
the most part of host reactions, both adaptive and innate
sections cooperate in the host’s protection and tissue damage.
However, the infection by microbial agents often occurs in
the peripheral tissues whereas specific naı¨ve T lymphocytes
are confined to lymphoid areas. Thus, the innate cells
recruited or resident in the tissues play a crucial role in the
containment of infection and the deployment of adaptive
immune response [5]. Like αβ T lymphocytes, γδ T cells
carry antigen T-cell receptors (TCR) that vary in the physical
properties of their ligand-binding sites [6]. Indeed, γδ TCR
have a great potential of diversity at their putative ligand-
binding sites as well as αβ T and B cells. This means that γδ T
cells have a potential to recognize diﬀerent pathogenic agents
through the recognition of common molecular patterns.
γδ T cells constitute a whole system of functionally
specialized subsets that have been implicated in the innate
responses against tumors and pathogens, the regulation of
immune responses, cell recruitment and activation, and
tissue repair [7]. The concept of γδ T cells as “first line
of defense” has been recently reviewed as a nonredundant
system of responses based on an innate immunity program
involved in systemic and specific responses depending on
the inflammatory microenvironment, on microbes features
and on signals that are engaged. This concept address facets
of a complex behaviour where several enigmas started to be
resolved. In humans and other primates, γδ T cells represent
a small percentage among peripheral blood lymphocytes (1–
5%) and represent a special case of CD3+ T cells relying
on their known separate set of receptor genes [8]. Thus,
γδ T cells are a specialized and independent population of
lymphocytes, and basing on TCR recombination diﬀerent
settings of γδ T cells may be now classified. The first γδ
T cell lineage appearing in the human foetal thymus uses
the Vδ1 chain paired with diﬀerent Vγ chains, and these
preferentially home in epithelial tissues as the intestine [9].
Vδ1 T cells constitute only a minor proportion of human
blood while they are a large population of the human
intraepithelial cells and have been found to enrich various
human epithelial tumors and lymphomas [10]. Vδ1 T cells
recognize stressed cells via presentation of self-lipids by
CD1 and/or expression of stress-induced molecules through
the NKG2D receptor. In contrast, Vγ9Vδ2 T cells are the
major subset of the adult peripheral blood of humans,
ranging from 80/90% of γδ T cell pool. They typically
recognize phosphomonoester molecules synthesized in the
mevalonate (MVA) and 1-deoxy-D-xylulose 5-phosphate
(DOXP) metabolic pathway [11]. These lymphocytes have
been defined “nonconventional” T cells, owing to several
distinguishing features that are shared with both innate and
adaptive immune cells. Since their discovery, γδ T cells have
been shown to play a significant role against pathogens and
tumors and they were placed in the innate immunity as cells
of immunosurveillance. In antitumor response, γδ T cells
show a high production of IFN-γ in the early development
of tumor [12, 13]. γδ T cells may recognize and kill tumor
cells through the engagement of NKG2D expressed on their
surface which binds MICA and MICB or retinoic acid early-
1, respectively, in humans and in mice. These ligands are
up-regulated on several tumor cells including melanoma
cells acting as target for their destruction by locally resident
intraepithelial lymphocytes (IEL) as well as other cytotoxic
lymphocytes. The binding can provide a costimulatory signal
for cell lysis [14–16].
Several studies have reported in vitro reactivity of both
human Vδ2 and Vδ1 against a broad range of tumor cell
lines, normal cells infected with viruses, parasites, and bac-
teria [7]. In respect to transformed cells, the range of tumor
cell lines recognized by Vγ9Vδ2 T cells is now extended to
either haematopoietic or solid tumors [16–18]. Both subsets
of human γδ T cells are able to recognize and destroy tumor
cells as well as produce proinflammatory and Th1 cytokines
through diﬀerent mechanisms. A direct implication of these
cells in vivo diseases is well accepted. However, distinct
mechanisms in the recognizing and the functions of Vδ2
and Vδ1 T cells have been demonstrated, according also to
diﬀerent tumors, infections, and environments.
The highly restricted T cell receptor V region repertoire
of γδ T cells is certainly one of the most salient features
distinguishing these lymphocytes from conventional MHC
restricted αβ T cells. Most Vγ9Vδ2 T cells react against
the same related set of nonpeptidic, phosphorylated anti-
gens [15, 16] that are produced by both microbial and
endogenous metabolites, whereas Vγ9Vδ1 T cells seem to
recognize heterogeneous yet undefined antigens, presumably
unrelated to Vγ9Vδ2 agonists. Vγ9Vδ2 T cell antigens are
recognized in a TCR-dependent manner and are referred
to as phosphoantigens. The most potent antigen appears
to be the hydroxydimetihyl-allyl-pirophosphate (HDMAPP),
an intermediate of DOXP pathway, restricted to plant
cells and some microorganisms. Metabolic intermediates as
isopentenyl pyrophosphate (IPP) can also activate Vγ9Vδ2
T cells although at concentrations of 100000-fold higher
than those for microbial agonists. These compounds derive
from the MVA pathway used by mammalian cells and
some bacteria and are essential for sterol synthesis, cell
growth, and membrane integrity. Aminobisphosphonate
(ABPs) compounds may also stimulate Vγ9Vδ2 T cells
through their ability to inhibit farnesyl pyrophosphate syn-
thase, an enzyme acting downstream of IPP synthesis along
MVA pathway, promoting intracellular accumulation of IPP.
Finally, the alkylamines remain a debated class of antigens.
Some studies strongly suggest that like ABPs, alkylamines
promote intracellular accumulation of Vγ9Vδ2 agonists
derived fromMVA pathway [19]. Although phosphoantigen-
mediated activation of Vγ9Vδ2 T cells clearly requires the
expression of TCR, as indicated by gene transfer approach,
how precisely this occurs remains unclear to date. The cell-
cell contact required for the activation implicates either
that phosphoantigens induce the structural modification of
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TCR or that are presented by surface molecules at present
undefined. Interestingly, Vγ9Vδ2 T cells have been recently
shown to recognize a complex formed between apolipopro-
tein A1 and ATP synthase, a mitochondrial enzyme that
is translocated on the surface of normal hepatocytes and
some tumor cell lines, in a TCR-dependent fashion [20].
Among other costimulatory factors, human Vγ9Vδ2 T cells
express frequently activating or inhibitor NK receptors such
as NKG2D or CD94/NKG2A that seem to be the major
contributing receptor to Vγ9Vδ2 T cell activation/inhibition
[21]. In the plethora of activation signals of human γδ T cells,
an important pathway is represented by Toll-like receptors
(TLR). TLRs have emerged as central regulators of innate
immunity being receptors specifically sensing molecular
patterns of microbes, leading to immediate cellular responses
through the activation of transcription factors, notably NF-
κb, AP-1, and IRF [22]. Although certain TLRs are expressed
on myeloid cells, several reports have shown functional
expression on B, αβ and γδ T cells [23]. It has been reported
that TLR ligands including TLR3 ligand poly (I:C) and
TLR9 ligand CpG enhance the activation of γδ T cells in
vitro via promoting type I IFN production in myeloid and
plasmacytoid dendritic cells (DCs), respectively [22]. More
recently, it has been shown that highly purified γδ T cells
expressed more TLR3 mRNA than αβ T cells, thus opening
the possibility that γδ T cells might respond directly to
TLR3 ligands in the absence of APC [24]. Taken together,
these results confirm that γδ T cells may play a crucial role
in innate immune response and studies on the diﬀerent
signals activating or enhancing their functions may help to
improve the understanding of these cells and their usage in
the immunotherapy.
Although immunological memory is a hallmark of
adaptive immune response, Vγ9Vδ2 T cells seem to show
some features of memory cells. Studies in monkeys suggested
that phosphoantigen-specific Vγ9Vδ2 T cells, expanded
during a primary TB vaccination, showed an accelerated
response after a secondary challenge [25]. The ubiquitous
nature of exogenous and endogenous phosphoantigens for
Vγ9Vδ2 T cells also suggests that the development of
memory state may be quite diﬀerent from conventional
cells, which are programmed to respond to foreign peptide
antigens. After antigen exposure, Vγ9Vδ2 T cells undergo
the same change of CD8 T cells. Basing on the expression
of CD45RA and CD27 molecules on their surface, it is
possible to distinguish 4 subsets of Vγ9Vδ2 T cells as
naı¨ve, central memory (TCM), eﬀector memory (TEM), and
terminal diﬀerentiated eﬀector cells (TEMRA). Vγ9Vδ2 T
cells acquire CD45RO expression like early memory CD8 T
cells and are termed central memory Vγ9Vδ2 T cells. They
lose CD27 and CD28 expression and re-express CD45RA
becoming terminally diﬀerentiated cells. Approximately 90%
of Vγ9Vδ2 T cells in the adult have a memory phenotype
[26]. Eﬀector memory Vγ9Vδ2 T cells represent a readily
available pool of antigen-primed Vγ9Vδ2 T cells which enter
the peripheral tissues, where they can eventually further
diﬀerentiate into CD45RA+CD27− cells, produce cytokines,
and exert cytotoxicity contributing to the containment of
invading microbial pathogens.
In TB, the establishment of the disease and its clinical
manifestations are closely linked to host’s immune response.
The spectrum of the immune response in TB ranges from
a protective response in latent TB, to the absence of
response and the dissemination of mycobacteria in miliary
TB. In pulmonary TB, there is an eﬀective antimycobacterial
response with a clinically progressive disease involving innate
and adaptive immune compartment [27].MTB cannot evade
the induction of cell-mediated immunity; MTB has evolved
to survive it, and survive it does—even if the initial infection
is successfully controlled, many infected individuals develop
a latent infection that can persist for decades. On the other
hand, some heavily MTB exposed individuals show no signs
of infection: no pathology, no symptoms, and no apparent
adaptive immune response. It is possible that in these cases,
the innate immune response has eliminated the pathogen at
the earliest stage [28]. Indeed, early immune mediators as
IFN-γ are produced initially by NK cells and γδ T cells before
adaptive T cells are instructed by IL-12 and IL-18 secreted
by antigen presenting cells (APC) as DCs and macrophages.
For this reason, we will focus the attention on γδ T cells
that represent an optimal bridge between innate and adaptive
immune response [29, 30]. Interestingly, the activity of a
subset of human γδ T cells in vitro and in vivo can be
stimulated by many nonpeptidic molecules (some drugs are
currently being tested in Phase I cancer trials). The relatively
low in vivo toxicity of many of these drugs makes possible
novel vaccine and immune-based strategies for infectious
diseases. Collectively this scenario indicates that diﬀerent
pathways and cell types interact to mediate innate immunity
against MTB providing mechanisms that could likely be
target for future therapeutic interventions in TB.
3. γδ T Cell Response in MTB Infection
In infections, responses of γδ T cells to MTB were described
as early as in 1989 [31]. Later, a range of studies described
a marked expansion of this subset in the blood of (TB)
patients and also with a range of other infections as
leprosy, malaria, salmonella, and Streptococcus pneumoniae.
Mycobacterial phosphoantigens were identified as potent
stimulators of Vγ9Vδ2 T cell functions [15]. Specifically,
Vγ9Vδ2 T cells predominate in mycobacterial infections
whereas Vδ1 T cells are preferentially expanded in HIV
patients and in immunocompromised subjects probably
undergoing CMV reactivation [32, 33]. Parallel to the studies
in murine models, an association between mycobacterial
and human Vγ9Vδ2 T-cell responses was rapidly estab-
lished. γδ T-cell clones were isolated from synovial fluid of
rheumatoid arthritis patients, which had been stimulated
with mycobacterial antigens and were found to proliferate
to mycobacterial antigens [34]. In vivo, γδ T cells were
observed in granulomatous skin reactions of leprosy patients,
and γδ cell lines derived from these persons proliferated to
mycobacterial extracts [35]. Direct evidence for the ability
of MTB to activate γδ T cells was provided by studies of
Kabelitz et al. which determined by limiting dilution analysis
that the majority of peripheral blood γδ T cells proliferated
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in response to a killed preparation of MTB bacilli [36].
Subsequently, the predominance of Vγ9Vδ2 T cells in TB
infection was confirmed [37]. Being MTB an intracellular
pathogen residing within mononuclear phagocytes, many
studies on the role of these cells in the activation of γδ T cells
following the infection of MTB rapidly appeared. Monocytes
infected with MTB were found to be eﬃcient accessory cells
for γδ T cells in a non-MHC restricted manner [38]. In vitro,
Havlir et al. demonstrated that monocytes infected with live
MTB bacilli were particularly eﬀective in expanding Vγ9Vδ2
T cells, compared to heat-killed bacteria and soluble protein
antigens of MTB [39]. Similarly, MTB-infected alveolar
macrophages, the first target of inhaled MTB, served as non-
MHC-restricted accessory cells for γδ T cells. There were
diﬀerences, however, between alveolar macrophages and
monocytes. At the high alveolar macrophage to T-cell ratios
normally present in alveolar spaces, expansion of resting γδ
T cells was inhibited by alveolar macrophages in a dose- and
cell-contact-dependent manner. However, upon invasion by
MTB, alveolar macrophages are certainly capable of serving
as accessory cells for γδ T cells, providing a mechanism for
γδ T-cell activation in the lung. γδ T cells are dependent
on costimulators for proliferation, cytokine secretion, and
expression of cytolytic eﬀector function. Like their αβTCR+
counterparts, γδ T cells are dependent upon interactions of
CD40-CD40L, CD28-B7.1/7.2, and CD2, as well as adhesion
molecules (CD2-LFA-3, LFA-ICAM) for co-stimulation, and
these second signals are readily provided by accessory cells
such as monocytes and alveolar macrophages [40]. Whether
accessory cells process and present mycobacterial antigens to
MTB activated γδ T cells, and thus serve as true antigen-
presenting cells, has yet to be determined.
The major eﬀector functions of T cells in the immune
response to MTB are cytokine secretion, cytotoxic eﬀector
function (CTL), and cell-contact-dependent “help”. The goal
of these eﬀector functions is to help to contain mycobacterial
growth and to stimulate memory immunity. Studies with
MTB antigen-activated γδ T-cell clones or primary cells
determined that there was some heterogeneity in cytokine
profile among clones [41]. There was no clear-cut Th-1
versus Th-2 dichotomy, nor there were major diﬀerences
found in cytokine patterns between 〈αβ TCR+ and γδ T-
cell clones〉. In general, most γδ T-cell clones produced
IFN-γ, a cytokine associated with protective immunity
to MTB, and a marker of the proinflammatory cytokine
environment characteristic of the cellular immune response
to intracellular bacteria. Some studies have used intracellular
staining for cytokines and determined that in response to
phosphoantigens, γδ T cells produce both TNF-α and IFN-γ
[42]. When MTB-activated CD4+ and γδ T-cell populations
from healthy tuberculin-positive donors were analyzed for
patterns of cytokine production in response toMTB-infected
monocytes, both subsets secreted large amounts of IFN-γ
[43]. Intracellular IFN-γ levels were similar between CD4+
and γδ T cells, suggesting more eﬃcient IFN-γ release by
γδ T cells. In contrast, CD4+ T cells produced more IL-
2 than γδ T cells, which correlated with diminished T-cell
proliferation of γδ T cells compared with CD4+ T cells.
CD4+ and γδ T cells from some healthy donors produced
IL-4, reemphasizing the absence of a Th-1 versus Th-2
dichotomy among these two T-cell subsets.
Although activated γδ T cells produce IL-2, they produce
far less IL-2 than CD4+ T cells, which accounts for their
poor proliferative ability and need for exogenous IL-2 to
induce γδ T-cell expansion [44]. Furthermore, IL-15 is a
T-cell growth factor for γδ T cells, and is produced by
mononuclear phagocytes, thus providing a link between
MTB-infected macrophages and γδ T-cell activation in the
absence of CD4+ T-cell responses [42]. The balance between
these two factors (CD4 versus macrophage “help”) may
account for the variability one observes in γδ physiology.
Finally, contribution of Vγ9Vδ2 T lymphocytes to immune
protection against MTB is based also on the cytotoxic
eﬀector functions of these cells. It was reported earlier that
Vγ9Vδ2 T lymphocytes kill macrophages harboring live
MTB through a granule-dependent mechanism, resulting in
killing of intracellular bacilli; moreover, it has been reported
that these cells reduce the viability of both extracellular and
intracellular MTB through granulysin and perforin, both
detected in Vγ9Vδ2 T lymphocytes. These findings have
suggested that Vγ9Vδ2 T lymphocytes directly contribute to
a protective host response against MTB infection [45].
A controversial feature of Vγ9Vδ2 T lymphocytes is
based on their capability to mount a memory response
against a microbial reinfection or reactivation. Vγ9Vδ2
T lymphocytes mount a response against MTB infection
during the early phases of infection, and a strong expansion
of this T cell subset has been observed in diﬀerent reports,
but their functional response against mycobacterial infection
seems not limited to an innate reaction. As mentioned above,
Vγ9Vδ2 T cells follow a phenotype diﬀerentiation similar
to αβ T cells and probably a certain memory response is
generated. Relevant studies in mice cannot be performed
because murine γδ T cells do not express the homolog of
Vγ9Vδ2 TCR, and there is no functional equivalent for these
cells, so far, identified inmice. A pioneering study showed the
capability to mount a memory response after microbial rein-
fection or reactivation [25]. Indeed, to examine a primary
role of γδ T cells during mycobacterial infection, macaques
inoculated with BCG were analysed for the change in the γδ
T cell repertoire. Striking expansion of Vγ9Vδ2 T cells were
detected in the blood after BCG inoculation, whereas there
was no apparent increase in other γδ T cell subsets. This
expansion indicated the development of primary response
of these cells during mycobacterial infection. Apart systemic
Vγ9Vδ2 T cells, other pools of expanding Vγ9Vδ2 T cells
have been observed in pulmonary and intestinal tissues
after intravenous BCG inoculation and only a small amount
of these cells were observed in lymph nodes suggesting
that tissues but not peripheral lymph node tissues could
expand in response to mycobacterial infection. Of note,
after a second inoculation of BCG, a marked re-expansion
of Vγ9Vδ2 T cells appeared in the blood. The expansion
of these cells after a reinfection was 2–9 times larger than
those seen during the primary infection. Furthermore, the
expansion was persistent for as long as 7 months after
the second BCG challenge [25]. This evidence provide that
Vγ9Vδ2 T cells underwent polyclonal expansion during
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a primary mycobacterial infection can mount a memory
recall response after a secondary challenge. Another impor-
tant result has been reported by other reports suggesting that
the route and the dose of mycobacterial infection related
to the expansion of γδ T cells. Systemic BCG inoculation
induced a dose-dependent expansion of circulating γδ T
cells as well as CD4 and CD8 T cells whereas, in the
pulmonary compartment, the systemic infection resulted in
a predominant increase in numbers of γδ T cells. In contrast,
pulmonary exposure to mycobacteria induced a detectable
expansion of CD4, CD8, and γδ T cells only in the lung but
not in the blood [46, 47]. The pattern and kinetics of γδ T cell
responses during mycobacterial infection might contribute
to characterizing immune protection against TB and testing
new TB vaccines in primates.
4. γδ T Cells Cross-Talk with DCs during
Mycobacterial Infections
Recent knowledge about the interaction between apparently
diﬀerent compartments of immune system changed the way
to consider the immune response and its regulation. Studies
in animal models suggest that even the smallest population of
immune cells in a site of infection can exert large biological
eﬀects up to systemic level. This recent concept is due
to the continuous interaction between local and recruited
innate immune cells with APCs. Indeed, γδ T cells and DCs
participate in early phases of immune response against MTB.
Continuous cross-talk between γδ T cells and myeloid cells is
evident in histological studies, in vitro culture experiments,
and in animal models. Indeed, γδ T cells participate in early
immune response against MTB producing cytokines (IFN-
γ and TNF-α) and chemokines, prompting cytotoxicity or
modulating other cell in mice [48].
The first evidence of an influence exerted by γδ T cells
on DCs system came from studies by Ismaili et al., showing
that human γδ T cells activated in vitro by phosphoantigens
are capable of inducing maturation of monocyte-derived
DCs [49] and this process involved both membrane-bound
(i.e., CD40L) and soluble (i.e., TNF-α and IFN-γ) T cell-
derived signals [49–51]. Recent studies support the notion
that DCs strengthen the cellular immune response against
mycobacterial infection [52–56]. Even if the critical role of
DCs in the initiation of immune response has been firmly
established [57], their involvement in immune responses
occurring at sites of MTB infection needs further elucida-
tions. DCs are highly represented at sites of MTB infection
at the onset of the inflammatory response [58], and it is
conceivable that immature DCs present in the lung mucosa
are specialized for antigen uptake and processing. After
interaction with pathogens, they mature and migrate to
lymphoid organs where they prime naı¨ve T cells through cell
surface expression ofMHC and costimulatory molecules and
the secretion of immunoregulatory cytokines such as IL-12.
Although infection with mycobacteria has been reported
to induce maturation of DCs, in vitro infection of human
mDC by virulent MTB strain H37Rv has been shown to
impair their maturation, reduce their secretion of interleukin
(IL)-12, and inhibit their ability to stimulate T cell prolifer-
ation [51, 59]. In vivo experiments demonstrated that MTB
aﬀects DC migration and antigen presentation, promoting
persistent infection in mice [60]. These findings suggest
that MTB can interfere with the host immune response
by hampering several functions of DCs, and in particular
suppressing the migration of mDCs and modulating its cell
traﬃcking ability, and these mechanisms may encourage
the long-term persistence of the bacilli in the host during
chronic infections. However, in more physiological situation,
such as during infection by a Vγ9Vδ2-stimulating pathogen
unable to promote complete DC maturation, it is easy to
hypothesize that many diﬀerent stimuli, besides microbial-
derived phosphoantigens, may influence the activation state
of DCs and Vγ9Vδ2 T cells. Accordingly, in a recent paper,
Meraviglia et al. demonstrated that Vγ9Vδ2 induce full mat-
uration of MTB-infected immature DCs, that were otherwise
unable to complete maturation. In detail, MTB infection
caused up-regulation of CD86 and HLA-DR molecules, but
not of CD80 and CD40, while the co-culture of MTB-
infected DCs with Vγ9Vδ2 T cells determined up-regulation
of CD80 and CD40 expression, no changes of HLA-DR
and CD86 expression, and a significant up-regulation of IL-
12p70 production, suggesting that Vγ9Vδ2 T cells mediate
full maturation of MTB-infected DC [61]. On the other
hand,MTB infected DCs lead to a rapid and strong activation
of co-cultured Vγ9Vδ2 T cells without requirement for any
additional stimulations. The MTB infected DC-mediated
potentiation of Vγ9Vδ2 T cell responses could be explained
at least in part by up-regulation and/or presentation of MTB
derived phosphoantigens to Vγ9Vδ2 T cells. However, and
most surprisingly, MTB infected DCs selectively induced
proliferative, but not cytokine or cytolytic responses by
Vγ9Vδ2 T cells and this was associated to the expansion of
phenotypically “immature”, central memory-type Vγ9Vδ2
T cells. Similar results have been obtained using BCG
infected DCs co-cultured with Vγ9Vδ2 T cells [62]. Possible
explanation for the incomplete phenotypic and functional
diﬀerentiation of Vγ9Vδ2 T cells include the lack of IL-15
production by MTB infected DCs; IL-15 is a relevant
cytokine for the diﬀerentiation of γδ cells [63], and its main
eﬀect in the pathway leading to diﬀerentiation of Vγ9Vδ2
T cells towards eﬀector memory cells was associated with
induction of Bcl-2 expression and resistance to cell death
[63]. Indeed, adding IL-15 to co-cultures of MTB infected
DCs and Vγ9Vδ2 T cells caused eﬃcient diﬀerentiation of
γδ T cells with maintenance of the central memory pool
and with generation of eﬀector-memory and terminally
diﬀerentiated eﬀector memory cells, which displayed potent
antimycobacterial function, as demonstrated by their ability
to eﬃciently reduce the viability of intracellular MTB. We
therefore conclude that mechanisms fine-tuning the DC-γδ
T cells cross talk are still not clear, including identification
of the critical receptor/ligand interactions, as well as the
underlying molecular mechanisms; therefore, further studies
are needed such as the analysis of the eﬀect of inhibitors
of various signalling cascades coupled with transcriptome
analysis of maturing DCs at various time points after
Vγ9Vδ2 T cell incubation.
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5. Incomplete Maturation of γδ T Cells in
TB Patients
A number of studies have attempted to determine the in vivo
role of γδ T cells in the human immune response to MTB.
Barnes et al. established that patients with pulmonary or
miliary TB had a diminished ability to expand γδ T cells in
vitro in response to heat-killedMTB and IL-2, although there
was quite a range of γδ T-cell expansion among the diﬀerent
groups [64]. Some investigators have suggested an increase in
peripheral γδ T cells in patients with TB or among hospital
workers with contact with TB patients but this has not been
a consistent finding [65, 66]. Studies of T-cell phenotype in
bronchoalveolar cells from healthy PPD+ subjects and from
aﬀected and unaﬀected lungs of patients with pulmonary TB
found a T lymphocytic alveolitis in the aﬀected tuberculous
lung [67]. γδ T cells were found among the lymphocytes
in this alveolitis, but their proportion was not increased
relative to αβ T cells. Thus γδ T cells are present in situ
in pulmonary TB but are not expanded compared to γδ T
cells in peripheral blood or unaﬀected lung. The presence
of γδ T cells in the tuberculous lung is consistent with the
findings that alveolar macrophages can serve as APCs for γδ
T cells. In the study by Schwander et al., monocytes were
markedly increased in alveolar spaces of tuberculous lung
[67]. Monocytes also are eﬃcient APCs of γδ T cells, and
hence in TB adequate accessory cell populations are available
for γδ T-cell activation.
More recently, dramatic expansion of Vγ9Vδ2 T cells
has been found after BCG vaccination in infants, and
several phosphorylated antigens derived from mycobacte-
ria have been defined [68]. It is already known in the
context of a natural infection the consistent expansion of
Vγ9Vδ2 T cells with a TCM phenotype in the peripheral
blood of patients with active TB, which was accompa-
nied by the dramatic reduction of the pool of Vγ9Vδ2
cells with immediate eﬀector functions (TEM and TEMRA
cells). However, this skewed representation of circulating
Vγ9Vδ2 T cell phenotypes during active TB was transient
and completely reversed after successful antimycobacterial
therapy. This explains previous findings from Dieli’s group,
showing that Vγ9Vδ2 T cells from children aﬀected by active
TB have an increased proliferative activity, but decreased
IFN-γ production and granulysin expression [69]. After
successful chemotherapy, the Vγ9Vδ2 T cell proliferative
response strongly decreased, whereas IFN-γ and granulysin
production consistently increased.
Other previous observations have indicated an increased
proliferative activity of Vγ9Vδ2 T cells from patients with
TB [70, 71] but reduced production of IFN-γ, compared
with that of healthy tuberculin reactors [72]. Additionally,
Dieli et al. reported that decrease of Vγ9Vδ2 T cell eﬀector
functions involves not only IFN-γ production but also
expression of granulysin, a molecule known to be responsible
for the killing of MTB [69]. The reason for the loss of
Vγ9Vδ2 T cell eﬀector functions during TB is unknown. One
possibility is that sustained in vivomycobacterial stimulation
of Vγ9Vδ2 T cells causes their apoptosis [73]. For example,
high levels of bacteria (such as those occur in patients with
TB), resulting from the inability to contain and prevent their
spread, would presumably result in chronic stimulation of
eﬀector Vγ9Vδ2 T cells by mycobacterial antigens and in
their apoptosis, thus providing an explanation for why this
population of γδ T cells is lost in patients with active disease
but recovers after drug therapy. Alternatively, it is possible
that reduced IFN-γ and granulysin expression in children
with TB, which recovers after disease improvement, could
be the consequence of generalized illness. The finding that
IFN-γ and granulysin production are restored by successful
chemotherapy, which is suggested to induce the generation
of a protective immune response, strongly supports this
possibility. Another possible explanation for the incomplete
phenotypic and functional diﬀerentiation of Vγ9Vδ2 T cells
could be explained by the lack of relevant cytokines secreted
by MTB infected DCs. In fact, it has been previously shown
that, diﬀerentiation of Vγ9Vδ2 TCM cells into TEM and TEMRA
cells occurs upon antigen stimulation in the presence of IL-
15, while any other tested cytokine, including IL-7, had no
such eﬀect [63]. The main eﬀect of IL-15 in the pathway
leading to diﬀerentiation of Vγ9Vδ2 T cells towards eﬀector
memory cells was associated with resistance to cell death
and Bcl-2 expression. Meraviglia et al. demonstrated that
the lack of IL-15 production by MTB infected DCs was not
due to the fact that MTB simply does not induce synthesis
of this cytokine, rather it actively inhibits IL-15 secretion.
Additionally, and similar to the in vitro data, their analyses
of IL-15 serum levels in healthy contact (HC) subjects and
TB patients showed that IL-15 production is not induced
in patients with active TB, but increases after completion of
chemotherapy [61]. However, the analysis of Vγ9Vδ2 T cell
functions in TB patients and especially in the site of infection
needs further investigations.
6. γδ T Cells Producing IL-17: Possible
Involvement in Mycobacterial Infection
The cytokine IL-17 has received considerable attention since
the discovery of a distinct CD4+ T helper cell subset produc-
ing it, known as Th-17 profile. This discovery provided com-
pelling reasons to explore outside the Th-1/Th-2 paradigm,
searching new answers to explain independent eﬀector T cell
responses. A rapid succession of studies defined the Th-17
cell paradigm, in which IL-6/STAT3 activation of the tran-
scriptional regulator retinoic acid receptor-related orphan
receptor-γt (RORγt) controls the lineage fate of IL-17A-,
IL-17F-, IL-21-, and IL-22-producing T cells (collectively
known as Th-17 cells) that are highly responsive to IL-1
receptor 1 (IL-1R1) and IL-23R signaling [74]. IL-17A has
been reported to participate in host defense against various
types of pathogen [75, 76] and estimated to be an important
cytokine in the immune response against mycobacterial
infection [77]. Indeed, IL-17 is produced immediately after
pulmonary BCG infection and was also detected at later
stages of MTB infection in mice [78]. Interestingly, IL-
17-expressing cells in the mycobacterial infected lungs in
murine models are γδ T cells rather than CD4+ T cells.
As mentioned, γδ T cells may play an important role in
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the eﬀector functions and regulation of immune responses to
infection of MTB, but the precise role of IL-17 producing γδ
T cells remains unclear. In a study performed on 27 patients
with active pulmonary TB and 16 healthy donors, it has
been found that proportion of IL-17-producing cells among
lymphocytes was similar between TB patients and HD,
whereas the proportions of γδ T cells in IL-17-producing
cells (59.2%) in peripheral blood were markedly increased
in TB patients when compared to those in HD. In addition,
the proportions of IFN-γ producing γδ T cells in TB
patients were obviously lower than that in HD. Upon re-
stimulated with MTB heat-treated antigen in vitro, fewer IL-
17-producing γδ T cells were generated from HD than TB
patients [79]. These findings were consistent with murine
investigations showing that the IL-17-producing γδ T cells
were main source of IL-17 in mouse model of BCG infection,
suggesting that γδ T cells might be involved in the formation
of tubercular granuloma in pulmonary TB patients [80], but
these investigations need further identification in humans.
Another study showed the diﬀerentiation and distribution
of human IL-22-producing T cells in a nonhuman primate
model of MTB infection. Since IL-22-producing T cells also
produce IL-17, knowledge about this cytokine profile may
help the understanding of the Th-17 profile. An apparent
increase in the number of T cells capable of producing IL-22
de novo without in vitro Ag stimulation has been observed in
lungs compared to blood and lymphoid tissues. Consistently,
IL-22-producing T cells were visualized in situ in lung TB
granulomas, indicating that mature IL-22-producing T cells
were present in TB granuloma. Surprisingly, phosphoantigen
HMBPP activation of Vγ9Vδ2 T cells down-regulated the
capability of T cells to produce IL-22 de novo in lymphocytes
from blood, lung/BAL fluid, spleen and lymph node. Up-
regulation of IFN-γ-producing Vγ9Vδ2 T eﬀector cells
after phosphoantigen stimulation coincided with the down-
regulated capacity of these T cells to produce IL-22 de
novo [81]. These findings raise the possibility to ultimately
investigate the function of IL-22 producing T cells and
to target Vγ9Vδ2 T cells for balancing potentially hyper-
activating IL-22 producing T cells in severe TB.
7. γδ T Cell-Specific Phosphoantigen
Based-Immunotherapy in TB: Lesson
from the Cancer
As mentioned above, γδ T cells have antimicrobial as well as
antitumor activity through the production of proinflamma-
tory cytokines, chemokines, and cytotoxic molecules such as
perforins and granzymes. This suggests their involvement in
the control of infections in vivo and could be considered as
target for new intriguing therapeutic approaches. Moreover,
the capacity of γδ T cells to interfere in DC functions
would allow their use in specific immunotherapy. Although
other nonclassical lymphocytes may support DC maturation
and contribute to the antigen presentation, γδ T cells
in humans represent an easy model to amplify the DC
system. Given that the diﬀerent classes of pharmacolog-
ical agents are used in therapies for diﬀerent diseases,
the possibility to make new vaccines or adjuvants based on
these compounds is very close. A variety of natural and
synthetic nonpeptidic antigens have been demonstrated to
activate γδ T cells such as IPP, dimethylallyl diphosphate
(DMAPP), geranylgeranyl pyrophosphate (GGPP) including
Nitrogen containing bisphosphonates (N-Bps). At present
two approaches showed exciting results. Tumor immune
evasion mechanisms are common and include the down-
regulation of tumor-associated antigens, MHC, and cos-
timulatory molecules. By contrast to αβ T cells, γδ T cells
are not MHC restricted and show less dependence on
costimulatory molecules such as CD28. Moreover, γδ T cells
are involved in the resistance of cutaneous carcinogenesis in
mice and display potent cytotoxicity against various human
tumor cell lines in vitro. Indeed, human Vγ9Vδ2 T cells
expanded in vitro and transferred to immunodeficient mice,
xenografted with tumor cells, showed eﬃcacy against B cell
lymphoma, melanoma, and renal carcinoma [82]. On this
ground, in patients with multiple myeloma or with low-
grade non-Hodgkin lymphoma, occurrences of acute phase
reaction to intravenously injection of an aminobisphos-
phonate, called Pamidronate (PAM), were attributed to the
systemic activation of γδ T cells [83], and this provoked the
deliberate treatment of lymphoma patients with PAM and
IL-2. Promising results were achieved after the patients were
prescreened for substantively response to PAM and IL-2 of
γδ T cells in vitro. By several criteria, zoledronate is more
potent and eﬃcacious than PAM. Previous studies in patients
with breast and prostate tumors showed that zoledronate
induced in vivo activation of peripheral γδ T cells into more
potent cytotoxic and IFN-γ producing cells. Recently, a phase
I clinical trial in metastatic HRPC has been conducted by
Dieli et al. to determine the safety, feasibility, and response
induced by Vγ9Vδ2 T cells in vivo, using zoledronate alone or
in combination with low-doses of IL-2 [84]. The encouraging
prospect that the activation of peripheral blood Vγ9Vδ2
T cells can be eﬃcacious against solid tumors could be
explained by the double role played by these cells; activated
γδ T cells can infiltrate tumor sites and display cytotoxic
activity against tumor cells or they help other cells as DCs
to trigger an adequate specific CD8 T cell immune response.
Diﬀerent interesting results have been shown in animal
models aimed to improve the eﬀectiveness of vaccination
against TB. As known, although the vaccination with BCG
protects children against disseminated TB, it is now clear
that it does not protect eﬃciently against pulmonary disease.
Therefore, the ever-increasing incidence of TB worldwide
urges to improve this vaccine. It is widely accepted that one
of the best immunological predictors of protective and long-
lasting immunity to TB is a high frequency of MTB-specific
IFN-γ-secreting cells (ISCs) in the peripheral blood [85]. A
quantitatively sizeable population of eﬀector T cells able to
release IFN-γ seems to promote the protective bioactivity
of infected macrophages. Therefore, most of current TB
vaccine candidates and injection regimens aim to increase
the frequency of these MTB-specific ISC. These candidates
comprise recombinant BCG, attenuated MTB, modified vac-
cinia virus, naked DNA, and subunit combinations of either
MTB protein antigens or recombinant fusion proteins [86].
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It exists now a consensus on the ability of heterologous
prime-boosts regimens to induce high titers of MTB-specific
ISC. The priming with an optimized “starter” such as BCG
or improved BCG could likely induce a broad diversity of
memory cells. The further boost with antigens common to
the priming would expand and diﬀerentiate into eﬀector
memory, MTB-specific ISC. The immunodominant protein
antigens from MTB include members of the “proline-
proline-glutamic acid family” proteins (Mtb39a-e), Mtb9.9,
TB10.4, so-called “6-kDa early secretory antigenic target”
(ESAT-6), andmycolyl transferase complex Ag85A, B, C [86].
Despite their good specificity, these purified antigens were
weakly immunogenic when injected alone, and therefore
needed to be combined either to other antigens (hybrid
proteins) or to adjuvants. Hybrids of the most promising
proteic antigens, namely, Mtb72F and H-1 have been gen-
erated: they corresponded to fusions Mtb39 to Mtb32 and
ESAT-6 tomycolyl transferase complex antigen 85B (Ag85B),
respectively. Hybrid H-1 is highly specific of MTB and
induces a detectable ISC population but its immunogenicity
was quite low, even after several boosts. Therefore, H-1
was combined with adjuvants such as Lipovac or IC31.
Nonhuman primates γδ T cells like those from rhesus
macaques present a TCRwith similarity of 90% to the human
Vγ9Vδ2 TCR sequence, and the same pattern of specificity
for phosphoantigens [44]. Therefore, these animals represent
a model suited to investigate the role of phosphoantigen-
induced γδ T cell responses in immunity to TB. A pioneering
analysis of rhesus infected with MTB demonstrated that
rhesus γδ T lymphocytes mounted memory responses to
mycobacteria. This adaptive response correlated with a faster
γδ T cell expansion in the secondary respect to primary
exposure to mycobacteria and was associated with a reduced
bacteremia and protection against fatal TB. Furthermore,
two studies have independently shown that blood γδ T
cells from several monkey species could be monitored using
mAb reagents for human T cells. These studies confirmed
that phosphoantigen-induced proliferation of naı¨ve, central
memory CD27+, and eﬀector memory CD27− γδ T cells
require IL-2 in vivo [87]. Since macaque γδ T cells seem
to react as human Vγ9Vδ2 T cells during BCG vaccination
or TB infection and to phosphoantigen stimulation, the
bioactivity of a synthetic phosphoantigen combined to a
subunit vaccine candidate for TB has been assessed in vivo.
Since TB mainly alters cytokine production and cytotoxic
activity but not proliferation of human γδ T cells, this
study focused on eﬀector functions in defence against
TB: secretion of Th-1 cytokines, most notably IFN-γ, and
perforin [88]. In this paper, an eﬃcient immunogenicity
against MTB antigens in naı¨ve cynomolgus after a prime-
boost with the hybrid H-1 solubilized in Lipovac adjuvant
with or without the synthetic phosphoantigen Picostim has
been reported. Although the IC31 adjuvant was selected
for clinical trial of the H-1 subunit vaccine, in this work
the adjuvant Lipovac was preferred for its lower bioactivity,
in order to be able to detect additional adjuvant eﬀect
on phosphoantigens. However, Picostim, a new generation
of synthetic phosphoantigens, induced immediate cytokine
production by γδ T cells (IL-2, IL-6, IFN-γ, and TNF-α),
but a subsequent anergy up to 4 months after the initial
administration. This phenomenon could be related to the
TCR down-modulation/regulation or apoptosis induced cell
death [73, 89]. However, this early γδ response translates
into diﬀerential induction of recall response eliciting the H-
1-specific αβ T cell responses, which essentially comprised
recall of cytotoxic αβ T lymphocytes specific for Ag85B
and few ISC αβ T lymphocytes in both groups of animals.
So this study demonstrated that a prime-boost regimen
with the H-1/phosphoantigen combination added a primary
wave of adaptive immune responses from phosphoantigen-
specific γδ T cells to the secondary wave of H-1-specific αβ
T cells. In summary, nonhuman primates vaccinated with
phosphoantigens associated to a subunit of antituberculosis
vaccine, mounted a diﬀerential immune response by αβ
or γδ T cells, where boosts anergized γδ T cells but
promoted αβ recall responses. Finally, these models of
usage of phosphoantigens against tumors and infections may
allow to design subunit combinations promoting memory
by both classes of lymphocytes in order to improve TB
therapy.
8. Concluding Remarks
γδ T cells appear to combine properties of both adaptive and
innate immunity. The identification of unusual compounds
that are recognized by human γδ T cells but not by αβ T
cells has recently stimulated great interest in the development
of γδ T cell-based therapies. In contrast to other potential
eﬀector cells, it is possible to envisage combined in vivo
activation and adoptive cell therapy with ex vivo expanded
γδ T cells, because several drugs as ABPs and synthetic
phosphoantigens are licensed for clinical application and in
clinical trials, respectively. Recent advances on their multipo-
tent functions, not only to the innate immune response, but
to DC and antigen presentation system, increase the interest
in a possible usage in clinical treatments. The eﬀectiveness
of these compounds in stimulating a cytotoxic response
against tumors, as well as amplifing the antigen presentation
of soluble specific peptides through DCs, represents a new
possibility in the approaches based on immune cells.
Furthermore, the intriguing capacity of γδ T cells to
naturally respond to particular infections, such as TB, put
these cells in a central place mainly in those pathologies
where the classical presentation of antigens is compromised.
However, γδ T cells are part of the multicellular immune
system that is tightly regulated by multiple pathways and
cells including the regulatory cells. We still know very
little about the nature of γδ T cell antigens, their precise
recognition mechanism, and their therapeutic relevance.
Also the mechanisms regarding DC/γδ T cells cross talk
are still not clear, as the receptors and ligands involved in
this interaction, the molecular factors, and the possibility
to verify this interaction in a model in vivo. Future studies
should also address the possible advantage of combining γδ T
cell therapy with conventional therapy or other therapeutical
approaches.
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